Share on StockTwits
 

Gilead Sciences (NASDAQ:GILD) EVP Kevin Young unloaded 100,000 shares of Gilead Sciences stock on the open market in a transaction that occurred on Thursday, January 23rd. The shares were sold at an average price of $81.44, for a total transaction of $8,144,000.00. Following the completion of the transaction, the executive vice president now directly owns 216,418 shares in the company, valued at approximately $17,625,082. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

Gilead Sciences (NASDAQ:GILD) traded down 2.18% on Monday, hitting $78.86. The stock had a trading volume of 13,648,602 shares. Gilead Sciences has a 1-year low of $39.24 and a 1-year high of $84.40. The stock has a 50-day moving average of $74.92 and a 200-day moving average of $66.74. The company has a market cap of $120.9 billion and a P/E ratio of 44.37.

Gilead Sciences (NASDAQ:GILD) last released its earnings data on Tuesday, October 29th. The company reported $0.52 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.48 by $0.04. The company had revenue of $2.78 billion for the quarter, compared to the consensus estimate of $2.72 billion. During the same quarter in the previous year, the company posted $1.00 earnings per share. The company’s revenue for the quarter was up 14.7% on a year-over-year basis. On average, analysts predict that Gilead Sciences will post $2.00 earnings per share for the current fiscal year.

A number of research firms have recently commented on GILD. Analysts at Piper Jaffray raised their price target on shares of Gilead Sciences from $91.00 to $97.00 in a research note to investors on Thursday. Separately, analysts at TheStreet reiterated a “positive” rating on shares of Gilead Sciences in a research note to investors on Wednesday, January 15th. Finally, analysts at Nomura initiated coverage on shares of Gilead Sciences in a research note to investors on Wednesday, January 8th. They set a “buy” rating on the stock. Two analysts have rated the stock with a hold rating and twenty-three have issued a buy rating to the stock. Gilead Sciences currently has a consensus rating of “Buy” and an average price target of $80.00.

Gilead Sciences, Inc (NASDAQ:GILD) is a research-based biopharmaceutical company that discovers, develops and commercializes medicines.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.